Search
Displaying 121–130 of 543 for “Retinitis pigmentosa”
-
Beacon Stories
“If someone like me, a woman with retinitis pigmentosa and a part-time job, can leave a legacy gift, you can too! And trust me, it feels really, really good to know that part of your life’s work will contribute to something meaningful for future generations.”
-
Beacon Stories
Jen Walker was diagnosed with retinitis pigmentosa at 14 years old and didn’t feel ready to meet others with retinal diseases until many years later. Jen now wants to connect with others and raise awareness for the fighting blindness community.
-
Hannah Dreams Big Despite Vision Loss
Beacon StoriesHannah has always had dreams of starting her own fashion line. And despite being diagnosed with retinitis pigmentosa at the age of 15, she recently began an intimate company, Watson & Wilma.
-
Beacon Stories My Retina Tracker Patient Stories
Susan, who has retinitis pigmentosa, went through many tests in search of learning more about her eye disease. Once she enrolled in the My Retina Tracker® (MRT) testing program, Susan was provided with comprehensive results and a clear diagnosis, giving her clarity and hope.
-
Jack Sees a Different Life after LUXTURNA
Beacon StoriesJack Hogan was diagnosed with retinitis pigmentosa at only two-and-a-half years old. But with the help of connections made with the Foundation, Jack became the first-ever recipient of the FDA-approved gene therapy known as LUXTURNA.
-
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
Research NewsIn a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study
Research NewsFrancois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases.
-
Why Genetic Testing is Important
An Overview of Genetic Testing for Inherited Retinal Degenerative Diseases
-
First Patient Receives ProQR’s Emerging USH2A Therapy in Clinical Trial
Research NewsProQR, a developer of RNA therapies in the Netherlands, announced that the first clinical-trial participant has received its emerging treatment, which targets retinitis pigmentosa and Usher syndrome caused by mutations in exon 13 of the USH2A gene.
-
Encouraging Vision Improvements Reported in ReNeuron's Cell-Therapy Clinical Trial
Research NewsReNeuron, a cellular therapy developer in the UK, has reported vision improvements in the treated eyes of the first three retinitis pigmentosa (RP) patients in the Phase II part of the Phase I/II clinical trial for its proprietary human retinal progenitor cells (hRPC). The Phase I portion of the trial, completed last year, primarily assessed safety in subjects with minimal remaining vision.
